J.P. Marvel Investment Advisors LLC Has $4.22 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

J.P. Marvel Investment Advisors LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.4% during the third quarter, Holdings Channel reports. The firm owned 145,868 shares of the biopharmaceutical company’s stock after selling 590 shares during the period. J.P. Marvel Investment Advisors LLC’s holdings in Pfizer were worth $4,221,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Olistico Wealth LLC bought a new stake in Pfizer in the second quarter valued at $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at $29,000. Quarry LP bought a new stake in shares of Pfizer in the 2nd quarter worth about $31,000. Financial Connections Group Inc. acquired a new stake in shares of Pfizer during the 2nd quarter worth about $34,000. Finally, ESL Trust Services LLC bought a new position in Pfizer during the 1st quarter valued at about $37,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 0.4 %

Shares of Pfizer stock opened at $27.46 on Friday. The company has a market capitalization of $155.62 billion, a P/E ratio of 37.11, a price-to-earnings-growth ratio of 0.88 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The business has a 50-day moving average of $28.96 and a two-hundred day moving average of $28.64. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.17) EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.12%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is 227.03%.

Insider Activity

In other news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares in the company, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on PFE. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Citigroup assumed coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Finally, Wells Fargo & Company upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.